Ekso Bionics Holdings, Inc. (EKSO) Upgraded to “Buy” by Zacks Investment Research
Zacks Investment Research upgraded shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) from a hold rating to a buy rating in a research note released on Wednesday. They currently have $2.00 price target on the stock.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, B. Riley reiterated a buy rating and issued a $4.00 price objective on shares of Ekso Bionics Holdings in a research report on Monday, May 15th.
Shares of Ekso Bionics Holdings (NASDAQ EKSO) opened at 1.73 on Wednesday. The company has a 50-day moving average of $1.95 and a 200 day moving average of $2.80. The stock’s market cap is $44.35 million. Ekso Bionics Holdings has a one year low of $0.99 and a one year high of $6.55.
Ekso Bionics Holdings (NASDAQ:EKSO) last released its quarterly earnings data on Tuesday, May 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.03. The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.38 million. Ekso Bionics Holdings had a negative return on equity of 788.27% and a negative net margin of 392.15%. On average, equities analysts forecast that Ekso Bionics Holdings will post ($0.71) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Ekso Bionics Holdings stock. Carl Domino Inc boosted its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 74.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 82,054 shares of the company’s stock after buying an additional 35,088 shares during the period. Carl Domino Inc owned 0.32% of Ekso Bionics Holdings worth $190,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.42% of the company’s stock.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.